New Venturetec reported earnings results for the fiscal year ended September 30, 2016. For the period, the company reported loss of USD 60,649,374 or USD 12.09 per share, compared to a gain of USD 15,105,459 or USD 3.00 per share in the fiscal year 2015. The main reason for the loss was the decrease of the quoted share price of Osiris Therapeutics from USD 18.47 per share to USD 4.96 per share or negative 73.2% and the decrease of the traded share price of Myriad Genetics from USD 37.48 to USD 20.58 or 45.1%. The net asset value per September 30, 2016 is USD 4,721,747. Due to the loss of the fiscal year 2016 the assets of the company did not cover one-half of the share capital anymore in accordance with Art 725 para.1 CO.